SCHEMBL10037569

SCHEMBL10037569

CCNC(=O)C(C)(C)N1C(=O)C=CC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
NPSR1 Q6W5P4 3/20 0.35
MGLL Q99685 3/20 0.35
MAPT P10636 3/20 0.35
BLM P54132 2/20 0.35
LMNA P02545 2/20 0.35
GMNN O75496 1/20 0.35
THPO P40225 1/20 0.35
PMP22 Q01453 1/20 0.35
HPGD P15428 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
WRN Q14191 1/20 0.35
HIF1A Q16665 1/20 0.35
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
HTT P42858 2/20 0.33
HSP90AA1 P07900 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19661507 0.73 CYP26A1 (0.34) ALDH1A1BLMHPGDCYP1A2CYP2C19
SCHEMBL19882366 0.72 TSHR (0.33) MAPTLMNASMN1; SMN2PKM
SCHEMBL20161211 0.72 MGLL (0.36) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL10037570 0.70 P2RX4 (0.33) ALDH1A1MAPT
SCHEMBL11509113 0.70 MGLL (0.38) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL19134323 0.69 MGLL (0.39) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL18391260 0.69 MGLL (0.36) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL7962613 0.69 MGLL (0.36) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL13632716 0.67 MGLL (0.41) ALDH1A1NPSR1MGLLMAPTBLM
SCHEMBL3665093 0.67 GSK3A (0.52) ALDH1A1NPSR1MGLLMAPTBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124791-B2 Active energy ray curable liquid composition and liquid cartridge CANON KABUSHIKI KAISHA (JP) 2012-02-28 US disclosed
US-20100094024-A1 ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE CANON KABUSHIKI KAISHA (JP) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094024-A1 ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE C9, MLX, CHRM1 ALDH1A1 3555/4885NPSR1 1256/4885MGLL 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.